Medical School · Year 3 · Family Medicine · includes a quiz and discussion video

Seminar 05: Diabetes Management in Primary Care

Year 3: Family Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Screen and diagnose type 2 diabetes and prediabetes
2. Set individualized glycemic targets
3. Select appropriate pharmacotherapy
4. Monitor and adjust treatment
5. Screen for and manage diabetes complications
6. Apply lifestyle interventions for diabetes

Seminar Outline

I. Diagnosis and Screening

Diabetes mellitus diagnosis relies on demonstrating chronic hyperglycemia through standardized laboratory criteria. A fasting plasma glucose of 126 mg/dL or higher, a two-hour oral glucose tolerance test value of 200 mg/dL or higher, or a hemoglobin A1c of 6.5 percent or higher each establish the diagnosis when confirmed on repeat testing in the absence of unequivocal hyperglycemic symptoms. A random glucose of 200 mg/dL or higher in a patient with classic symptoms of hyperglycemia including polyuria, polydipsia, and unexplained weight loss confirms diabetes without requiring repeat testing. When results fall near diagnostic thresholds, repeat testing using the same method helps confirm or exclude the diagnosis.

Prediabetes identifies individuals at elevated risk for progression to diabetes, defined by fasting glucose between 100 and 125 mg/dL, two-hour post-load glucose between 140 and 199 mg/dL, or A1c between 5.7 and 6.4 percent. The United States Preventive Services Task Force recommends screening adults aged 35 to 70 years who are overweight or obese, representing a Grade B recommendation. Earlier screening is appropriate for individuals with additional risk factors including family history of diabetes, high-risk ethnic background, history of polycystic ovary syndrome, hypertension, or dyslipidemia. Women with prior gestational diabetes require screening every three years, while individuals with prediabetes warrant annual glucose testing given their five to ten percent annual conversion rate to diabetes.

Distinguishing type 1 from type 2 diabetes carries important therapeutic implications. Type 1 diabetes typically presents in younger patients with acute onset, often including diabetic ketoacidosis, and results from autoimmune destruction of pancreatic beta cells causing absolute insulin deficiency. Type 2 diabetes usually develops in adults through progressive insulin resistance and relative insulin deficiency, often presenting insidiously with gradual symptom development or detection through screening in asymptomatic individuals. Measurement of C-peptide levels, which are low or absent in type 1 and normal or elevated in type 2, helps clarify uncertain cases. Type 1 diabetes always requires insulin therapy, while type 2 diabetes may be managed initially with lifestyle modification and oral agents.

Prediabetes management aims to prevent or delay progression to diabetes through intensive lifestyle intervention. The landmark Diabetes Prevention Program demonstrated that achieving seven percent weight loss and 150 minutes weekly of moderate physical activity reduces diabetes incidence by 58 percent. Structured lifestyle programs modeled on this intervention provide education, behavioral support, and accountability to help participants achieve these targets. Metformin represents a pharmacologic option for high-risk individuals with prediabetes, particularly those under age 60, those with body mass index above 35, and women with prior gestational diabetes, though lifestyle intervention remains more effective.

<image>Panel A: Diagnostic criteria chart comparing fasting glucose, OGTT, A1c, and random glucose thresholds for diabetes and prediabetes. Panel B: Screening recommendation flowchart showing USPSTF guidelines and risk factor considerations. Panel C: Comparison table distinguishing type 1 versus type 2 diabetes by onset, mechanism, presentation, treatment, and C-peptide. Panel D: Prediabetes intervention outcomes showing relative risk reduction with lifestyle versus metformin.</image>

II. Glycemic Targets

Hemoglobin A1c targets require individualization based on patient characteristics rather than uniform application of a single goal. For most adults with diabetes, an A1c target below seven percent balances meaningful microvascular complication reduction against hypoglycemia risk. Younger, healthier patients with short disease duration and low hypoglycemia risk may benefit from more intensive targets below 6.5 percent. Conversely, older adults, those with limited life expectancy, extensive comorbidities, or significant hypoglycemia history warrant relaxed targets below eight percent that prioritize safety and quality of life over intensive glucose control.

Self-monitoring blood glucose targets complement A1c goals with real-time feedback that guides day-to-day management decisions. Recommended fasting glucose targets generally range from 80 to 130 mg/dL, with peak post-meal values ideally remaining below 180 mg/dL. Bedtime glucose between 80 and 180 mg/dL helps prevent nocturnal hypoglycemia while avoiding sustained hyperglycemia overnight. These targets require individualization based on hypoglycemia risk, with wider acceptable ranges appropriate for patients prone to low blood sugar or those with hypoglycemia unawareness.

Time in range represents an emerging metric enabled by continuous glucose monitoring technology that captures glucose patterns more comprehensively than A1c or intermittent self-monitoring. The goal for most patients is maintaining glucose between 70 and 180 mg/dL for more than seventy percent of the time. Equally important are targets limiting time below range: less than four percent below 70 mg/dL and less than one percent below 54 mg/dL to minimize hypoglycemia burden. These metrics prove particularly valuable for patients using continuous glucose monitors, offering insights into glucose variability and patterns that A1c alone cannot reveal.

Multiple factors influence appropriate glycemic targets for individual patients. Hypoglycemia risk represents perhaps the most important consideration, as patients with impaired hypoglycemia awareness, those on insulin or sulfonylureas, and those with renal impairment require more conservative targets. Longer diabetes duration typically correlates with diminished benefit from intensive control due to established complications and reduced beta cell reserve. Shorter life expectancy shifts priorities from long-term complication prevention toward symptom management and quality of life. Significant comorbidities compete for management attention and may make intensive glycemic control less feasible or beneficial. Patient preferences regarding treatment intensity deserve incorporation into shared target-setting discussions.

<image>Panel A: A1c target ladder showing different targets for various patient populations with rationale. Panel B: Glucose target ranges for fasting, post-prandial, and bedtime with individualization notes. Panel C: Time in range visualization showing target distribution across glucose ranges. Panel D: Spider diagram of factors influencing glycemic target individualization.</image>

III. Lifestyle Management

Medical nutrition therapy forms the foundation of diabetes management, with evidence supporting multiple dietary approaches rather than a single prescribed diet. Individualized nutrition plans should align with patient preferences, cultural backgrounds, and practical constraints while emphasizing consistent carbohydrate intake and selection of lower glycemic index foods. Both Mediterranean and DASH dietary patterns demonstrate effectiveness for glycemic control. The plate method provides a simple visual tool: half the plate with non-starchy vegetables, one quarter with lean protein, and one quarter with carbohydrate-containing foods. Weight loss of five to seven percent in overweight patients consistently improves glycemic control, often reducing or eliminating medication requirements.

Physical activity improves insulin sensitivity, aids weight management, and provides cardiovascular benefits independent of weight loss. Recommendations call for at least 150 minutes weekly of moderate-intensity aerobic exercise such as brisk walking, or 75 minutes of vigorous activity, spread across at least three days without gaps exceeding two consecutive days. Resistance training two to three days weekly builds muscle mass that enhances glucose disposal. Combining aerobic and resistance exercise produces superior glycemic benefits compared to either modality alone, with typical A1c reductions of 0.5 to 0.7 percent. Reducing prolonged sedentary time through brief activity breaks every 30 minutes provides additional metabolic benefit.

Weight management strategies vary based on degree of obesity and patient preferences. Dietary approaches should focus on creating sustainable caloric deficits rather than specific macronutrient compositions, as various dietary patterns can effectively produce weight loss when caloric intake decreases. Exercise alone produces modest weight loss but significantly aids weight maintenance and provides independent health benefits. Pharmacotherapy for obesity deserves consideration in patients with body mass index of 27 or above who have diabetes, with GLP-1 receptor agonists serving dual roles for both conditions. Bariatric surgery produces substantial sustained weight loss and diabetes remission rates exceeding fifty percent in appropriate candidates with BMI of 35 or above and inadequately controlled diabetes.

Diabetes self-management education and support (DSMES) provides structured programs that build patient knowledge and skills for daily diabetes management. Education should occur at diagnosis, annually thereafter, and during transitions such as medication changes or development of complications. Core topics include glucose monitoring techniques, medication administration and timing, carbohydrate counting and meal planning, physical activity integration, and recognition and treatment of hypoglycemia. Delivery through individual or group sessions both prove effective, with program participation consistently associated with A1c reductions of approximately 0.6 percent and improved clinical outcomes. Certified diabetes care and education specialists lead these programs in most healthcare settings.

<image>Panel A: Visual plate method diagram with food group proportions and example meals. Panel B: Physical activity prescription showing aerobic and resistance recommendations with glucose-lowering effect. Panel C: Weight management intervention ladder from lifestyle through pharmacotherapy to surgery with BMI thresholds. Panel D: DSMES program components with timing of education delivery.</image>

IV. Pharmacotherapy Overview

Metformin remains the recommended initial medication for most patients with type 2 diabetes based on its efficacy, safety, and low cost. This biguanide decreases hepatic glucose production and improves insulin sensitivity, producing A1c reductions of one to 1.5 percent. Benefits include weight neutrality or modest weight loss, cardiovascular safety, and minimal hypoglycemia risk when used alone. Gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort affect many patients but often resolve with gradual dose titration starting at 500 mg daily and increasing over weeks. Metformin is contraindicated at estimated glomerular filtration rate below 30 mL/min and should be used cautiously between 30 and 45. Long-term use warrants periodic vitamin B12 monitoring due to malabsorption.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as essential second-line agents, particularly for patients with cardiovascular disease, heart failure, or chronic kidney disease. Empagliflozin, canagliflozin, and dapagliflozin block glucose reabsorption in the proximal renal tubule, producing glucosuria that lowers blood glucose independent of insulin. Beyond glycemic control, these agents provide weight loss of two to three kilograms, blood pressure reduction of three to five mmHg, and proven cardiovascular and renal protective effects. Notable risks include genital mycotic infections, volume depletion especially with diuretics, and rare euglycemic diabetic ketoacidosis. These medications require adequate renal function for glucose-lowering efficacy but provide renal protection even at lower GFR levels.

Glucagon-like peptide-1 (GLP-1) receptor agonists represent another cornerstone class offering glycemic control with substantial weight loss and cardiovascular protection. Semaglutide, dulaglutide, and liraglutide enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety. A1c reductions range from one to 1.5 percent, with weight loss often exceeding five percent of body weight. Cardiovascular outcome trials demonstrate reduced major adverse cardiovascular events with certain agents. Administration requires subcutaneous injection weekly or daily for most formulations, though oral semaglutide provides an alternative. Gastrointestinal side effects including nausea and vomiting limit tolerability for some patients, while rare pancreatitis warrants counseling.

Additional medication classes serve specific roles in diabetes pharmacotherapy. Sulfonylureas including glipizide, glyburide, and glimepiride stimulate insulin secretion independent of glucose, offering effective and inexpensive glycemic control but causing weight gain and hypoglycemia. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin and linagliptin provide modest A1c reduction with excellent tolerability and weight neutrality. Thiazolidinediones including pioglitazone improve insulin sensitivity but carry risks of heart failure exacerbation, weight gain, and fractures. Insulin remains the most effective glucose-lowering therapy, offering unlimited efficacy limited only by hypoglycemia and weight gain, with flexible dosing to match individual needs.

<image>Panel A: Metformin profile showing mechanism, efficacy, benefits, side effects, and contraindications. Panel B: SGLT2 inhibitor class overview with agents, mechanisms, glycemic and non-glycemic benefits, and risks. Panel C: GLP-1 receptor agonist comparison showing formulations, efficacy, and cardiovascular outcomes. Panel D: Summary grid of other diabetes medication classes with key characteristics.</image>

V. Treatment Algorithm

Initial therapy selection for newly diagnosed type 2 diabetes depends on clinical presentation and glycemic severity. Most patients start with metformin combined with therapeutic lifestyle changes. When metformin is contraindicated due to renal impairment or intolerance, SGLT2 inhibitors or GLP-1 receptor agonists serve as effective alternatives. Patients presenting with A1c above ten percent or with symptomatic hyperglycemia including significant polyuria, polydipsia, or weight loss may benefit from initial insulin therapy to rapidly control glucose and relieve symptoms, with potential transition to oral agents once stability is achieved.

Second-line medication selection should be driven by comorbidities rather than glucose-lowering efficacy alone, as modern agents offer comparable A1c reduction with differing ancillary benefits. For patients with established atherosclerotic cardiovascular disease, GLP-1 receptor agonists or SGLT2 inhibitors with proven cardiovascular benefit represent preferred additions to metformin. Heart failure with reduced ejection fraction strongly favors SGLT2 inhibitors given their unique benefits in this population. Chronic kidney disease indicates SGLT2 inhibitors or GLP-1 receptor agonists for their renal protective effects. When cost and access represent primary constraints, sulfonylureas or thiazolidinediones remain appropriate options. For patients where weight reduction is the dominant priority, GLP-1 receptor agonists or SGLT2 inhibitors address both glucose and weight.

Treatment intensification follows a stepwise approach for patients not achieving glycemic targets. If dual therapy with metformin and one additional agent proves insufficient, adding a third oral or injectable agent from a different class often achieves goal. Triple oral therapy combining metformin with two complementary agents represents one option. Injectable therapy intensification may involve adding a GLP-1 receptor agonist if not already prescribed or initiating basal insulin. The combination of GLP-1 receptor agonists with basal insulin proves particularly effective by addressing both fasting and post-meal glucose excursions while partially offsetting insulin-associated weight gain.

Insulin initiation becomes necessary when oral and non-insulin injectable agents fail to achieve targets or when clinical circumstances require it. Starting doses of basal insulin typically range from ten units or 0.1 to 0.2 units per kilogram daily, with bedtime dosing of intermediate or long-acting formulations. Dose titration increases insulin every three to seven days based on fasting glucose results until targets are achieved. When basal insulin alone at adequate doses fails to control post-meal glucose, adding prandial rapid-acting insulin before the largest meal and subsequently additional meals implements basal-bolus therapy. Premixed insulin formulations offer simplified regimens at the cost of reduced flexibility.

<image>Panel A: Initial therapy decision tree based on presentation, A1c level, and metformin tolerance. Panel B: Second-line selection algorithm organized by comorbidity priorities with preferred agents. Panel C: Intensification pathway showing progression from monotherapy through triple therapy to insulin. Panel D: Insulin initiation protocol with starting doses, titration schedule, and progression to basal-bolus.</image>

VI. Monitoring

Hemoglobin A1c monitoring frequency depends on treatment stability and goal attainment. Patients with stable glycemic control who have achieved their individualized A1c target require testing every six months to confirm maintained control. Those undergoing treatment changes or not yet at goal benefit from more frequent A1c checks every three months to assess response and guide further adjustments. Newly diagnosed patients typically receive quarterly testing initially as treatment regimens are established and optimized.

Self-monitoring of blood glucose (SMBG) frequency varies based on treatment regimen and individual patient needs. Patients using multiple daily insulin injections benefit from testing before meals and at bedtime to guide dosing decisions. Those on basal insulin alone typically need fasting glucose checks with additional testing as needed to evaluate patterns. Patients using non-insulin therapies may test less frequently, primarily to understand how food, activity, and medications affect their glucose, with individualized frequency based on treatment stability. Continuous glucose monitoring offers an alternative to SMBG for insulin-treated patients, providing comprehensive data on glucose trends, patterns, and time in range.

Additional monitoring addresses treatment effects and comorbidities. Annual fasting lipid panels assess cardiovascular risk and response to statin therapy, with more frequent testing during medication adjustments. Serum creatinine and estimated GFR require at least annual measurement, with more frequent assessment for patients on SGLT2 inhibitors, ACE inhibitors, or ARBs, or those with declining renal function. Annual urine albumin-to-creatinine ratio screens for diabetic nephropathy. Potassium levels require monitoring for patients on medications affecting the renin-angiotensin system. Periodic vitamin B12 assessment is prudent for patients on long-term metformin therapy.

Assessing treatment response requires integrating multiple data sources over appropriate timeframes. Expected A1c reductions range from 0.5 to 1.5 percent per medication depending on the agent and starting A1c level. Full A1c response takes approximately three months to manifest, as this measurement reflects average glucose over the preceding two to three months. When patients fail to respond as expected, adherence assessment should precede treatment intensification, as non-adherence commonly explains apparent treatment failure. Clinical inertia, the failure to intensify treatment when indicated, represents a major barrier to achieving glycemic targets and should be actively avoided.

<image>Panel A: A1c monitoring schedule by clinical scenario with testing frequency recommendations. Panel B: Self-monitoring guidance by treatment regimen showing testing times and frequencies. Panel C: Comprehensive monitoring checklist showing all recommended tests with frequencies. Panel D: Response assessment timeline showing when to expect changes and when to reassess treatment.</image>

VII. Complication Screening

Cardiovascular complications represent the leading cause of morbidity and mortality in diabetes, requiring systematic risk reduction. Blood pressure should be assessed at every clinical encounter with targets generally below 130/80 mmHg. Annual lipid panels guide statin therapy, with moderate or high-intensity statins recommended for most adults with diabetes between ages 40 and 75. Low-dose aspirin may be considered for patients at elevated atherosclerotic cardiovascular disease risk after shared decision-making weighing bleeding risks. ACE inhibitors or angiotensin receptor blockers provide additional benefit for patients with hypertension or albuminuria.

Diabetic nephropathy screening and management prevent progression to end-stage kidney disease. Annual estimated GFR and urine albumin-to-creatinine ratio assessments detect early kidney involvement. Positive screening is defined as UACR exceeding 30 mg/g on two of three samples collected over three to six months. First-line treatment includes ACE inhibitors or ARBs titrated to maximum tolerated doses, which provide renoprotection independent of blood pressure effects. SGLT2 inhibitors offer additional renal protection and should be added for patients with albuminuria or GFR below 60. Referral to nephrology is indicated when GFR falls below 30 mL/min or declines rapidly.

Diabetic retinopathy detection requires regular dilated fundus examinations by eye care professionals. For type 2 diabetes, initial examination should occur at diagnosis with annual repeat examinations thereafter. Patients with type 1 diabetes should begin screening within five years of diagnosis. Pregnant patients require examination before conception or during the first trimester with repeat assessment each trimester given accelerated retinopathy risk. When no retinopathy is present on consecutive examinations, extending the interval to every two years is acceptable. Findings of proliferative retinopathy or macular edema require prompt ophthalmology referral for treatment.

Diabetic neuropathy encompasses multiple forms requiring routine screening and symptomatic management. Annual comprehensive foot examinations should assess for peripheral neuropathy using 10-gram monofilament testing and vibration sense, along with inspection for foot deformities and skin changes. Patients with identified neuropathy require education regarding daily foot self-examination and appropriate footwear. Autonomic neuropathy may manifest as orthostatic hypotension, gastroparesis, or erectile dysfunction, warranting symptom-directed inquiry. Painful diabetic neuropathy treatment options include gabapentin, duloxetine, and pregabalin, each offering moderate efficacy for this challenging symptom.

<image>Panel A: Cardiovascular risk reduction checklist with blood pressure, lipid, and aspirin recommendations. Panel B: Nephropathy screening and treatment pathway from UACR measurement through ACEi/ARB and SGLT2i therapy. Panel C: Retinopathy screening schedule by diabetes type and pregnancy status with examination intervals. Panel D: Neuropathy assessment components showing sensory examination techniques and treatment options.</image>

VIII. Hypoglycemia

Hypoglycemia classification defines severity levels that guide treatment approaches. Level 1 hypoglycemia occurs with glucose between 54 and 70 mg/dL, representing an alert value indicating need for carbohydrate intake. Level 2 hypoglycemia at glucose below 54 mg/dL is clinically significant and requires prompt treatment. Level 3 hypoglycemia describes severe episodes requiring assistance from another person for treatment due to altered consciousness or behavior. These definitions enable consistent communication about hypoglycemia severity and inform treatment intensity decisions, as patients with frequent level 2 or any level 3 episodes require regimen modification.

Multiple risk factors predispose patients to hypoglycemia. Insulin therapy carries the highest risk, particularly with intensive regimens using multiple daily injections or pump therapy. Sulfonylureas cause hypoglycemia through glucose-independent insulin secretion, with longer-acting agents like glyburide posing greater risk than shorter-acting alternatives. Renal impairment prolongs medication action through impaired clearance. Elderly patients have blunted counter-regulatory responses and may develop hypoglycemia unawareness after repeated episodes. Alcohol consumption impairs hepatic gluconeogenesis. Tight glycemic control, while reducing complications, inherently increases hypoglycemia frequency.

Prevention strategies address modifiable risk factors systematically. Patient education ensures recognition of hypoglycemia symptoms, appropriate treatment, and understanding of precipitating factors. Frequent glucose monitoring identifies patterns predicting hypoglycemia risk. Medication adjustment reduces doses of insulin or sulfonylureas when hypoglycemia occurs recurrently. Consistent meal timing and carbohydrate intake prevent mismatches between medication action and food availability. Alcohol counseling addresses the specific risks of drinking without food. For patients with hypoglycemia unawareness, temporary relaxation of glycemic targets helps restore awareness through avoidance of any hypoglycemia for several weeks.

Treatment follows the rule of 15 for conscious patients: consume 15 grams of fast-acting carbohydrate such as four glucose tablets, four ounces of juice, or regular soda, wait 15 minutes, recheck glucose, and repeat treatment if glucose remains below 70 mg/dL. For severe hypoglycemia in unconscious patients unable to safely swallow, glucagon injection or nasal spray should be administered by caregivers or emergency personnel while awaiting medical assistance. Intravenous dextrose provides definitive treatment in healthcare settings. Following any hypoglycemic episode, patients should consume a snack containing protein and carbohydrate to prevent recurrence as the initial treatment wears off.

<image>Panel A: Hypoglycemia level definitions with glucose values and clinical characteristics. Panel B: Risk factor assessment checklist identifying patients at elevated hypoglycemia risk. Panel C: Prevention strategy framework addressing medication, monitoring, education, and lifestyle factors. Panel D: Rule of 15 treatment protocol with carbohydrate options and escalation for severe episodes.</image>

IX. Special Situations

Hospitalized patients with diabetes require adjusted management protocols that differ from outpatient regimens. Target glucose ranges of 140 to 180 mg/dL balance hyperglycemic and hypoglycemic risks in acute illness. Insulin typically becomes necessary as stress hormones impair glycemic control and oral agents may be contraindicated. Metformin should be held during acute illness with potential for lactic acidosis including sepsis, contrast administration, or significant renal or hepatic impairment. SGLT2 inhibitors require discontinuation during acute illness due to ketoacidosis risk and volume concerns. Transition back to home regimens requires careful planning as acute illness resolves and oral intake normalizes.

Sick day management guidelines help patients safely navigate acute illnesses at home. Insulin should never be discontinued during illness even if eating less, as stress hormones increase glucose production and insulin requirements often rise. Glucose monitoring frequency should increase to every four hours or more often. Adequate hydration with calorie-containing fluids if not eating normally prevents dehydration and ketosis. Patients with type 1 diabetes or those prone to ketosis should monitor ketones and seek care if moderate or large ketones develop. Contact with healthcare providers is indicated for persistent vomiting, glucose above 300 mg/dL, positive ketones, or inability to maintain hydration.

Perioperative diabetes management requires coordination with surgical teams. Metformin and SGLT2 inhibitors should be held for 24 to 48 hours before surgery to prevent lactic acidosis and ketoacidosis respectively. Surgery day insulin management depends on the procedure length and whether the patient will eat postoperatively; typically, long-acting insulin continues at reduced doses while short-acting insulin is held until eating resumes. Frequent glucose monitoring throughout the perioperative period guides supplemental insulin administration. Home medications resume when the patient is eating normally and cleared by the surgical team.

Pregnancy presents unique diabetes management challenges requiring specialized care. Women with preexisting diabetes planning pregnancy should optimize glycemic control beforehand, targeting A1c as close to normal as safely achievable to minimize congenital malformation risk. Gestational diabetes screening occurs at 24 to 28 weeks gestation using glucose tolerance testing. Pregnancy glucose targets are more stringent than non-pregnant values: fasting below 95 mg/dL, one-hour postprandial below 140 mg/dL, and two-hour postprandial below 120 mg/dL. Insulin is the preferred medication during pregnancy, though metformin is sometimes used. Postpartum glucose testing at four to twelve weeks identifies women requiring ongoing diabetes treatment.

<image>Panel A: Hospital glucose management protocol showing targets, insulin use, and medication holds. Panel B: Sick day management rules for patients covering insulin, monitoring, hydration, and when to call. Panel C: Perioperative timeline showing which medications to hold and when to resume. Panel D: Pregnancy glucose targets and management pathway from preconception through postpartum.</image>

X. Patient-Centered Care

Diabetes distress describes the emotional burden of living with diabetes, affecting up to forty percent of patients at some point. Common manifestations include burnout from the relentless demands of daily self-management, fear of hypoglycemia that leads to intentional hyperglycemia, and frustration with lack of progress despite effort. Acknowledging this burden and simplifying regimens when possible helps reduce distress. Distinguishing diabetes distress from clinical depression matters, as diabetes-specific concerns may respond better to diabetes education and support than to antidepressant medication. Referral to mental health professionals integrated with diabetes care addresses more severe psychological impacts.

Cultural considerations shape diabetes management in diverse populations. Dietary recommendations must account for culturally significant foods and traditional eating patterns rather than imposing unfamiliar diets unlikely to be followed. Health beliefs about diabetes causation, the role of medications, and the meaning of chronic illness vary across cultures and influence treatment acceptance. Language barriers require professional interpreter services rather than reliance on family members who may filter or modify communication. Family involvement expectations differ across cultures, with some expecting collective decision-making while others prioritize individual autonomy. Culturally concordant providers and community health workers can bridge gaps between clinical recommendations and cultural contexts.

Adherence challenges require identification of specific barriers before implementing solutions. Medication cost represents a common barrier addressable through generic substitutions, manufacturer assistance programs, and selection of lower-cost alternatives when clinically appropriate. Regimen complexity can be simplified through combination medications, once-daily dosing, and reduction of marginally beneficial agents. Side effects causing distress should prompt medication switches or dose adjustments. Knowledge gaps identified through teach-back confirm understanding and reveal educational needs. Motivational barriers may respond to collaborative goal-setting and diabetes education that connects treatment to personal values.

Shared decision-making integrates patient preferences with clinical evidence across diabetes management decisions. A1c target selection should incorporate patient perspectives on treatment intensity, hypoglycemia tolerance, and quality of life priorities. Medication choice discussions should present options with their benefits, risks, and practical considerations including administration route, monitoring requirements, and costs, allowing patients to weigh factors according to their values. Monitoring frequency balances clinical utility against patient burden and preference. Lifestyle change priorities should focus on modifications the patient feels motivated and able to achieve rather than clinician-imposed prescriptions.

<image>Panel A: Diabetes distress spectrum showing common concerns and intervention approaches. Panel B: Cultural considerations framework organized by diet, beliefs, language, and family factors. Panel C: Adherence barrier assessment and solution matching guide. Panel D: Shared decision-making model showing integration of clinical evidence with patient preferences.</image>

Summary

• Diagnosis requires fasting glucose at or above 126 mg/dL, A1c at or above 6.5 percent, or two-hour OGTT at or above 200 mg/dL; confirm if asymptomatic
• A1c targets should be individualized: below 7 percent for most adults; adjusted based on hypoglycemia risk, comorbidities, and life expectancy
• Metformin remains first-line therapy for most patients; discontinue if eGFR falls below 30 mL/min
• SGLT2 inhibitors provide cardiovascular and renal protection; add for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease
• GLP-1 receptor agonists offer significant weight loss and cardiovascular protection; prioritize if atherosclerotic cardiovascular disease or weight is primary concern
• Second-line medication selection should be driven by comorbidities including cardiovascular disease, heart failure, and kidney disease rather than glucose-lowering alone
• Complication screening includes annual dilated eye examination, comprehensive foot examination, urine albumin-to-creatinine ratio, and eGFR
• Hypoglycemia treatment follows the rule of 15: fifteen grams of fast-acting carbohydrate, wait fifteen minutes, recheck, and repeat if needed
• Sick day rules emphasize never stopping insulin, increasing monitoring, maintaining hydration, and checking ketones in at-risk patients
• Diabetes distress is common; address through acknowledgment, regimen simplification, and connection to diabetes education and support resources

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown